A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Unknown status
CT.gov ID
NCT00267657
Collaborator
(none)
30
1
10
3
Study Details
Study Description
Brief Summary
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Assessment of Interactions Between IV Methamphetamine and Reserpine
Study Start Date
:
Jan 1, 2004
Study Completion Date
:
Nov 1, 2004
Outcome Measures
Primary Outcome Measures
- Craving []
- Cardiovascular []
- Subjective symptoms/Mood Effects []
- CNS norepinephrine turnover []
Eligibility Criteria
Criteria
Ages Eligible for Study:
21 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Please contact site for more details
Exclusion Criteria:
- Please contact site for more details
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | U of CA, San Francisco | San Francisco | California | United States | 94143 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Reese Jones, M.D., Langley Porter Psychiatric Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00267657
Other Study ID Numbers:
- NIDA-CPU-0006-1
First Posted:
Dec 21, 2005
Last Update Posted:
Jan 11, 2017
Last Verified:
Dec 1, 2005